TY - JOUR
T1 - Frequency and management of maternal infection in health facilities in 52 countries (GLOSS)
T2 - a 1-week inception cohort study
AU - Bonet, Mercedes
AU - Brizuela, Vanessa
AU - Abalos, Edgardo
AU - Cuesta, Cristina
AU - Baguiya, Adama
AU - Chamillard, Mónica
AU - Fawole, Bukola
AU - Knight, Marian
AU - Kouanda, Seni
AU - Lumbiganon, Pisake
AU - Nabhan, Ashraf
AU - Nadisauskiene, Ruta J.
AU - Abdulkadir, Abdulfetah
AU - Adanu, Richard MK
AU - Aman, Mohammad Iqbal
AU - Arriaga Romero, William E.
AU - Assarag, Bouchra
AU - Bloemenkamp, Kitty W.M.
AU - Boobekova, Aigul
AU - Budianu, Mihaela A.
AU - Cararach, Vicenç
AU - Castro, Rigoberto
AU - Cebekhulu, Sylvia
AU - Cecatti, José Guilherme
AU - Colmorn, Lotte Berdiin
AU - Curteanu, Ala
AU - Donati, Serena
AU - Einda, Hla Mya Thway
AU - El Deen, Yasser Salah
AU - El Kak, Faysal
AU - Elsheikh, Mohamed
AU - Escobar-Vidarte, Maria F.
AU - Espinoza, Marisa Mabel
AU - Estrada, María Ester
AU - Gadama, Luis Aaron
AU - Goufodji, Sourou B.
AU - Hamid, Saima
AU - Hernandez Munoz, Rosalinda
AU - Herrera Maldonado, Nazarea
AU - Jayaratne, Kapila
AU - Kabylova, Saule
AU - Kristufkova, Alexandra
AU - Kumar, Vijay
AU - Lissauer, David
AU - Mereci, Wilson
AU - Minkauskiene, Meile
AU - Moreira, Philippe
AU - Munjanja, Stephen
AU - Osman, Nafissa B.
AU - Rijken, Marcus J.
N1 - Funding Information:
We sincerely thank the women who participated in this study. WHO is grateful to the extensive network of institutions and individuals who contributed to the project design and implementation, including researchers, study coordinators, data collectors, data clerks, and other partners including the staff from the Ministries of Health and WHO offices. We would like to acknowledge the contribution and lifelong achievements of our co-author Bukola Fawole, who passed away before the publication of this Article. This study is financially supported by the UNDP–UNFPA–UNICEF–WHO–World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Sexual and Reproductive Health and Research, WHO, Geneva, Switzerland (project A65787), Merck Sharp & Dohme, a wholly owned subsidiary of Merck (Kenilworth, NJ, USA), through its Merck for Mothers programme, and the United States Agency for International Development (grant GHA-G-00-09-00003). The views of the funding bodies have not influenced the content of this manuscript.
Funding Information:
We sincerely thank the women who participated in this study. WHO is grateful to the extensive network of institutions and individuals who contributed to the project design and implementation, including researchers, study coordinators, data collectors, data clerks, and other partners including the staff from the Ministries of Health and WHO offices. We would like to acknowledge the contribution and lifelong achievements of our co-author Bukola Fawole, who passed away before the publication of this Article. This study is financially supported by the UNDP?UNFPA?UNICEF?WHO?World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Sexual and Reproductive Health and Research, WHO, Geneva, Switzerland (project A65787), Merck Sharp & Dohme, a wholly owned subsidiary of Merck (Kenilworth, NJ, USA), through its Merck for Mothers programme, and the United States Agency for International Development (grant GHA-G-00-09-00003). The views of the funding bodies have not influenced the content of this manuscript. Editorial note: the Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.
Publisher Copyright:
© 2020 This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL
PY - 2020/5
Y1 - 2020/5
N2 - Background: Maternal infections are an important cause of maternal mortality and severe maternal morbidity. We report the main findings of the WHO Global Maternal Sepsis Study, which aimed to assess the frequency of maternal infections in health facilities, according to maternal characteristics and outcomes, and coverage of core practices for early identification and management. Methods: We did a facility-based, prospective, 1-week inception cohort study in 713 health facilities providing obstetric, midwifery, or abortion care, or where women could be admitted because of complications of pregnancy, childbirth, post-partum, or post-abortion, in 52 low-income and middle-income countries (LMICs) and high-income countries (HICs). We obtained data from hospital records for all pregnant or recently pregnant women hospitalised with suspected or confirmed infection. We calculated ratios of infection and infection-related severe maternal outcomes (ie, death or near-miss) per 1000 livebirths and the proportion of intrahospital fatalities across country income groups, as well as the distribution of demographic, obstetric, clinical characteristics and outcomes, and coverage of a set of core practices for identification and management across infection severity groups. Findings: Between Nov 28, 2017, and Dec 4, 2017, of 2965 women assessed for eligibility, 2850 pregnant or recently pregnant women with suspected or confirmed infection were included. 70·4 (95% CI 67·7–73·1) hospitalised women per 1000 livebirths had a maternal infection, and 10·9 (9·8–12·0) women per 1000 livebirths presented with infection-related (underlying or contributing cause) severe maternal outcomes. Highest ratios were observed in LMICs and the lowest in HICs. The proportion of intrahospital fatalities was 6·8% among women with severe maternal outcomes, with the highest proportion in low-income countries. Infection-related maternal deaths represented more than half of the intrahospital deaths. Around two-thirds (63·9%, n=1821) of the women had a complete set of vital signs recorded, or received antimicrobials the day of suspicion or diagnosis of the infection (70·2%, n=1875), without marked differences across severity groups. Interpretation: The frequency of maternal infections requiring management in health facilities is high. Our results suggest that contribution of direct (obstetric) and indirect (non-obstetric) infections to overall maternal deaths is greater than previously thought. Improvement of early identification is urgently needed, as well as prompt management of women with infections in health facilities by implementing effective evidence-based practices. Funding: UNDP–UNFPA–UNICEF–WHO–World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO, Merck for Mothers, and United States Agency for International Development.
AB - Background: Maternal infections are an important cause of maternal mortality and severe maternal morbidity. We report the main findings of the WHO Global Maternal Sepsis Study, which aimed to assess the frequency of maternal infections in health facilities, according to maternal characteristics and outcomes, and coverage of core practices for early identification and management. Methods: We did a facility-based, prospective, 1-week inception cohort study in 713 health facilities providing obstetric, midwifery, or abortion care, or where women could be admitted because of complications of pregnancy, childbirth, post-partum, or post-abortion, in 52 low-income and middle-income countries (LMICs) and high-income countries (HICs). We obtained data from hospital records for all pregnant or recently pregnant women hospitalised with suspected or confirmed infection. We calculated ratios of infection and infection-related severe maternal outcomes (ie, death or near-miss) per 1000 livebirths and the proportion of intrahospital fatalities across country income groups, as well as the distribution of demographic, obstetric, clinical characteristics and outcomes, and coverage of a set of core practices for identification and management across infection severity groups. Findings: Between Nov 28, 2017, and Dec 4, 2017, of 2965 women assessed for eligibility, 2850 pregnant or recently pregnant women with suspected or confirmed infection were included. 70·4 (95% CI 67·7–73·1) hospitalised women per 1000 livebirths had a maternal infection, and 10·9 (9·8–12·0) women per 1000 livebirths presented with infection-related (underlying or contributing cause) severe maternal outcomes. Highest ratios were observed in LMICs and the lowest in HICs. The proportion of intrahospital fatalities was 6·8% among women with severe maternal outcomes, with the highest proportion in low-income countries. Infection-related maternal deaths represented more than half of the intrahospital deaths. Around two-thirds (63·9%, n=1821) of the women had a complete set of vital signs recorded, or received antimicrobials the day of suspicion or diagnosis of the infection (70·2%, n=1875), without marked differences across severity groups. Interpretation: The frequency of maternal infections requiring management in health facilities is high. Our results suggest that contribution of direct (obstetric) and indirect (non-obstetric) infections to overall maternal deaths is greater than previously thought. Improvement of early identification is urgently needed, as well as prompt management of women with infections in health facilities by implementing effective evidence-based practices. Funding: UNDP–UNFPA–UNICEF–WHO–World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO, Merck for Mothers, and United States Agency for International Development.
KW - Adult
KW - Cohort Studies
KW - Female
KW - Global Health/statistics & numerical data
KW - Health Facilities/statistics & numerical data
KW - Humans
KW - Incidence
KW - Pregnancy
KW - Pregnancy Complications, Infectious/epidemiology
UR - https://www.scopus.com/pages/publications/85083674405
U2 - 10.1016/S2214-109X(20)30109-1
DO - 10.1016/S2214-109X(20)30109-1
M3 - Article
C2 - 32353314
AN - SCOPUS:85083674405
SN - 2214-109X
VL - 8
SP - e661-e671
JO - The Lancet Global Health
JF - The Lancet Global Health
IS - 5
ER -